Staphylococcus aureus Bacteremia and Buttonhole Cannulation: Long-Term Safety and Efficacy of Mupirocin Prophylaxis
|
|
- Dwayne Shaw
- 6 years ago
- Views:
Transcription
1 Staphylococcus aureus Bacteremia and Buttonhole Cannulation: Long-Term Safety and Efficacy of Mupirocin Prophylaxis Gihad E. Nesrallah,* Meaghan Cuerden,* Joseph H.S. Wong, and Andreas Pierratos *Division of Nephrology, The University of Western Ontario, London, Ontario, Canada; Department of Nephrology, Humber River Regional Hospital, Toronto, Ontario, Canada; Division of Nephrology, Queen Elizabeth Hospital, Hong Kong, SAR; and Division of Nephrology, The University of Toronto, Ontario, Canada Background and objectives: Buttonhole (constant-site) cannulation (BHC) continues to gain popularity with home and in-center dialysis programs worldwide. However, long-term safety data are lacking. This paper reports the authors singlecenter experience with Staphylococcus aureus bacteremia (SAB) and the efficacy of topical mupirocin prophylaxis (MP). Design, setting, participants, & measurements: This study was a retrospective prepost comparison of SAB rates after establishing MP. Fifty-six consecutive patients on home nocturnal hemodialysis via arteriovenous fistulae, mean age years, 38% women, and vintage months were observed for a total of 93.4 (pre-mp) and (post-mp) patient-years. Results: Ten episodes of SAB were observed, with metastatic complications in four cases, including pneumonia (n 2), septic arthritis, and a fatal C3 epidural abscess. When analyzed by observation period, the odds ratio (OR) for SAB before versus after the introduction of MP was 6.4 [95% confidence interval (CI) 1.3 to 32.3; P 0.02]. Two SAB episodes occurred after the MP started. Both patients had discontinued the MP for 3 weeks (nonadherent) preceding infection; hence, no SAB episodes were observed on treatment. In an as-treated analysis, the OR for SAB in the absence of MP was 35.3 (95% CI 2.0 to 626.7; P 0.01). Conclusions: BHC is associated with a significant risk of SAB with metastatic complications. In this prepost comparison of SAB rates, no infections were observed with MP. While awaiting more definitive studies, this simple intervention should be considered for patients using BHC. Clin J Am Soc Nephrol 5: , doi: /CJN Arteriovenous fistulae (AVF) are associated with better patient survival and lower infection risk when compared with central venous catheters (CVCs) and synthetic grafts; hence, they remain the preferred vascular access for patients receiving hemodialysis (HD) (1 6). The standard rope-ladder, or rotating-site technique, is the most commonly used method of cannulation with AVF. With this method, a new pair of venipuncture sites is used for each successive cannulation, thus allowing for skin healing to occur between dialysis sessions. The constant-site, or buttonhole cannulation (BHC) technique, has been in use since the 1970s (7,8) and has become increasingly popular among patients who selfcannulate (9), such as those receiving home HD. With the BHC technique, a limited number of puncture sites (typically three) are repeatedly cannulated, resulting in scarring with tract formation. Although published reports to date suggest that BHC is safe Received January 11, Accepted March 11, Published online ahead of print. Publication date available at Correspondence: Dr. Gihad Nesrallah, Humber River Regional Hospital, 200 Church Street, Toronto, Ontario, M9N 1N8. Phone: ; Fax: ; gnesrallah@hrrh.on.ca (9,10), long-term safety data are lacking. Vascular access-related bacteremia remains a major cause of morbidity and mortality among patients receiving HD. Although the incidence of bacteremia is relatively low among patients using AVF, several factors associated with BHC may increase the risk of infection with this technique. These include frequency of cannulation, longer dialysis time (as with nocturnal HD), self-cannulation in an unsupervised environment (home HD), and loss of skin integrity. In this report, we describe our center s experience with systemic infection rates among patients receiving home nocturnal HD via AVF, using BHC, and evaluate the efficacy of topical mupirocin in reducing rates of bacteremia with Staphylococcus aureus. Materials and Methods Study Design and Setting We undertook a retrospective prepost comparison of the frequency of bacteremic episodes related to BHC of native AVF in patients receiving home nocturnal HD at Humber River Regional Hospital, Canada, between January 1, 1998 and June 8, The primary outcome was the odds ratio (OR) for developing S. aureus bacteremia (SAB), comparing the periods before and after the implementation of a program-wide antimicrobial cream application procedure that began on January 1, Copyright 2010 by the American Society of Nephrology ISSN: /
2 1048 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , after several index cases with SAB. ORs comparing infection rates by treatment period and by actual treatment received were estimated. Infection rates among patients using the standard rope-ladder cannulation technique on conventional HD (CHD) at our full-care dialysis center were also reported for comparison. Exploratory analyses examined patient characteristics associated with an increased risk of SAB with BHC. Study Population Patients were included in this study if they were using a brachial or radial AVF, with self-cannulation, and BHC for home nocturnal HD. All consecutive patients training for home HD with AVF were offered the opportunity to learn the BHC technique and were not selected on the basis of cannulation difficulties such as aneurismal dilation, short usable segments, or cannulation pain. Training, Cannulation Procedure, and Intervention Patients learned the BHC technique during nocturnal HD training. Buttonholes were created by any one of five experienced nurses. Sharp needles were used for the first week, followed by blunt needles (Medisystems, Lawrence, MA) thereafter. Before cannulation, the fistula and surrounding skin were cleansed with chlorhexidine gluconate (0.5% in 70% alcohol) or providone-iodine solution. Scabs were covered with an alcohol pad for 5 minutes and then removed using a sterile needle. Mupirocin calcium 2% cream (Bactroban, Glaxo-Smith-Klein) was applied to each buttonhole with a sterile cotton swab after hemostasis was achieved and left to air dry. A single application was provided for each HD procedure. No dressings were applied. No patients received nasal antimicrobial prophylaxis or required methicillin-resistant S. aureus (MRSA) decolonization therapy. Sterile cannulation technique and adherence to the mupirocin cream was reviewed at each clinic visit (at 8-week intervals), but no specific techniques for verifying adherence were used. HD Prescriptions Home nocturnal HD patients received dialysis on alternate (every other) nights or 6 nights/wk for 6 to 10 hours per session using Fresenius 2008H or 2008K home HD machines. Prescription details are provided elsewhere (11,12). In-center patients received CHD for 3.5 to 4.5 h/session thrice weekly with conventional dialysate composition using Fresenius Optiflux NR or Polyflux (polyamide) dialyzers (Gambro Inc., Hechingen, Germany). The rope-ladder cannulation technique was used for all patients receiving CHD. Data Collection and Outcomes All blood culture results for the study cohort were extracted electronically from the hospital database and imported into a spreadsheet for analysis. Microbiology results from external laboratories were forwarded to our facility and collected prospectively. Patients presenting to an external facility with suspected infection were evaluated by the attending physician at our home dialysis unit within 24 hours of discharge and received instructions for home self-administration of antibiotics and further investigation if warranted. Microbiology laboratory staff were not aware of the study or intervention. Follow-up times were calculated starting from the date of first cannulation using BHC while receiving nocturnal home HD and ending at the time of any of the following exit events: transplantation, death, change of dialytic modality, access failure, or termination of the BHC technique for technical or other reasons. Statistical Methods Patients contributed variable lengths of follow-up time to either or both treatment periods. To use all available follow-up data, univariate logistic regression was used to calculate ORs for infection, comparing infection risk in the pre- and postintervention time periods. Computations were performed using PROC LOGISTIC in SAS (SAS statistical software, SAS Institute, Inc., Cary, NC). In the event of zero cells, 0.5 was added to each cell and ORs were calculated manually. Correlation within patients was not accounted for in the analyses; therefore, standard errors may have been underestimated, leading to an increased likelihood of rejecting the null hypothesis. Two-sided P values were considered significant at the 0.05 level, with 95% confidence intervals (CIs) reported. Results Study Subjects One hundred and thirty patients treated with home nocturnal HD were identified; 56 (43%) had AVF, 16 (12%) synthetic grafts, and 58 (45%) used CVCs. All patients with AVF used BHC and were included in the study. Baseline characteristics are shown in Table 1. All AVF were created at least 6 months before starting BHC. A total of six patients (10%) died (Table 2). Only one death was attributed to vascular-access-related infection. Other exit events included transplantation (n 8) and move to a new dialysis program (n 5). No AVF failures were documented during the entire study period. SAB A total of 11 blood cultures from 10 patients were positive for S. aureus during the study period (Table 3), all in association with local features of infection at the AVF. One was thought to represent a recurrent infection (see below). Six patients presented with features of local infection and fever. All six patients symptoms were resolved with a 2-week course of treatment with cefazolin. Four patients with SAB had evidence of metastatic infection. One patient had a cervical abscess compressing C3 to C7 that resulted in quadriplegia. This patient withdrew from HD and died. Two additional patients presented with local infection and clinical and radiographic features of pneumonia. Ventilation-perfusion scanning yielded a high probability of pulmonary embolism in both patients, suggesting septic pulmonary emboli from the infected AVF. Both patients made an uneventful recovery with a 2-week course of cefazolin with HD. One of these patients subsequently suffered a relapse of bacteremia 21 days after the initial infection, which resolved with a second identical course of antibiotic therapy. Endocarditis was excluded by transesophageal echocardiography. One patient presented with septic arthritis (left knee), as confirmed by joint aspirate, and required an extended course (6 weeks) of treatment with cefazolin. Oxacillin sensitivity was demonstrated for all episodes of SAB in the pre- and postintervention periods. One of the uncomplicated bacteremic episodes and the episode of recurrent bacteremia after pneumonia occurred after cream prophylaxis started. In both cases, the patients admitted to noncompliance with the cream for at least a 3-week duration before their infections.
3 Clin J Am Soc Nephrol 5: , 2010 Mupirocin Prophylaxis with Buttonhole Cannulation 1049 Table 1. Patient characteristics at first BHC use for home nocturnal HD (n 56) Mean age, years Female gender, n (%) 21 (38) Race, n (%) Caucasian 39 (70) black 5 (9) Asian 12 (21) Cause of ESRD, n (%) diabetes 12 (21) GN 30 (54) nephrosclerosis 6 (11) polycystic kidney disease 4 (7) obstructive uropathy 3 (5) interstitial nephritis 1 (2) Mean time on nocturnal HD, months SD HD frequency 6 sessions/wk, n 31 (55) (%) HD frequency 3.5 sessions/wk 25 (45) (alternate-night), n (%) Laboratory parameters (predialysis, mid-week), mean SD hemoglobin (g/l) creatinine (mg/dl) urea (mmol/l) albumin (g/dl) calcium (mg/dl) phosphorous (mg/dl) ferritin ( g/l) C-reactive protein (mg/l) Peripheral vascular disease, n (%) 6 (11) Current smoking, n (%) 3 (5) Receiving immunosuppressive 3 (5) therapy, n (%) October 30, 2006 for a total of 206,584 AVF-days (Table 4). In this cohort, only one episode of SAB was documented in association with local features of AVF infection, corresponding to a SAB rate of 0.005/1000 AVF-days. Patient Characteristics Associated with SAB The mean age of patients with SAB was years, with only one patient more than 55 years of age. The mean time on dialysis for this group was months. None of the patients with bacteremia smoked, were MRSA nasal carriers (by routine nasal swabs), or received immunosuppressive therapy (Table 5). Eight of 10 patients that developed SAB had an elevated C-reactive protein ( 8.0) level at baseline. Other Infections Additional abnormal blood culture results are shown in Table 3. Eight blood cultures were positive for coagulase-negative Staphylococcus in five patients, with evidence of a localized skin infection (of the AVF) in one patient, but no other clinical manifestations of systemic or local infection in the others. Follow-up cultures remained positive in two patients, and these patients received treatment. All of these infections occurred before introduction of mupirocin cream prophylaxis. There were three nonstaphylococcal infections: -hemolytic Streptococcus, Enterobacter cloacae, and Enterococcus faecalis. In the latter two infections, a urinary source was identified, and all episodes of bacteremia were successfully treated with intravenous antibiotics. Discussion Infection remains a major cause of morbidity and mortality in the HD population. The BHC technique has generally been regarded as safe, provided that rigorous skin cleansing and cannulation protocols are used (9,13,14). However, few studies to date have reported long-term safety data with BHC. In this retrospective prepost comparison, we documented a significant number of bacteremic episodes in patients using BHC before Main Study Outcomes A total of patient-years of follow-up were obtained. Using the intervention start date of January 1, 2004, this yielded 93.4 and patient-years before and after the introduction of the antimicrobial cream, respectively (Table 4). Before the introduction of mupirocin cream, a total of eight SAB episodes were documented. When analyzed by treatment period (regardless of treatment received), the infection rate was 0.32 infections/1000 AVF-days before the use of antimicrobial cream prophylaxis and 0.03 infections/1000 AVF-days after January 1, The OR for developing SAB before the introduction of mupirocin prophylaxis was 6.4 (95% CI 1.3 to 32.3; P 0.02). In the as-treated analysis, there were no infections in the intervention group, with an estimated OR of 35.3 (95% CI 2.0 to 626.7, P 0.01). Bacteremia in Conventional In-Center HD Using the Conventional Rope-Ladder Cannulation Technique A total of 298 patients with native AVF received CHD at Humber River Regional Hospital between January 1, 2002 and Table 2. Number of exit events and changes in dialysis frequency during the observation period (n 56 subjects) Nonaccess-related death 5 cardiovascular 4 ischemic bowel 1 Vascular access-related death (SAB with 1 epidural abscess, quadriplegia) Transplant 8 Move to new dialysis program 5 Change of modality 0 AVF failure 0 Switch from 3.5 sessions/wk to 6 sessions/wk a 8 Switch from 6 sessions/wk to 3.5 sessions/wk 0 a Alternate-night HD began in March 2004, after implementation of the antimicrobial cream prophylaxis protocol.
4 1050 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , 2010 Table 3. Summary of all positive blood cultures (n 22) obtained from 56 study patients during the observation period Causative Organism Number of Patients with Positive Culture (number of patients with one recurrent positive blood culture) Staphylococcus aureus 10 (1) Coagulase negative Staphylococcus 5 (3) Enterococcus faecaelis 1 Enterobacter cloacae 1 Hemolytic Streptococcus 1 Table 4. Follow-up times and SAB episodes before and after the introduction of the mupirocin cream prophylaxis start date (January 1, 2004) By Treatment Period a As-Treated b Preintervention follow-up time for entire cohort (years) mean SD follow-up time in years per (0.2 to 5.7) (0.2 to 5.7) subject (range) infection episodes 8 10 infection rate (events/1000 AVF-days) Postintervention follow-up time for entire cohort (years) mean SD follow-up time in years per (0.4 to 5.4) (0.4 to 5.4) subject (range) infection episodes 2 0 infection rate (events/1000 AVF-days) OR (95% CI) c 6.4 (1.3, 32.3) 35.3 (2.0, 626.7) CHD controls follow-up time for entire cohort (years) infection episodes 1 infection rate (events/1000 AVF-days) a Follow-up time on treatment calculated from January 1, 2004; infections attributed to study period. b Follow-up time on treatment calculated from actual intervention start date for subjects initially not adherent to study intervention (n 2); SAB episodes attributed to intervention status as-treated analysis. c OR as calculated by univariate logistic regression. the implementation of a program-wide antimicrobial cream prophylaxis protocol, with subsequent episodes documented only in patients who were nonadherent to the prescribed regimen. In addition, 4 of 10 of these infection episodes were complicated by metastatic spread, a potentially life-threatening complication of SAB. To our knowledge, this study represents the first-ever report of severe systemic infections associated with BHC. Reporting of infection rates with BHC has generally been anecdotal (9) and limited by the small cohort sizes (14). In the study presented here, the overall rate of infection was 0.23/ 1000 AVF-days in the preintervention period, which was similar to that observed in a recent multicenter Canadian cohort of CHD patients using rope-ladder cannulation (15). Although this study reported 5 bacteremic episodes per 10,000 treatments (or 0.21 episodes/1000 AVF-days), measures were not taken to confirm AVF as the source of infection, and the actual SAB rate related to AVF may have been closer to that observed in our CHD cohort (0.005 infections/1000 AVF-days). Comparing the rates of SAB in patients in our study cohort with those using rope-ladder cannulation with full-care CHD, a 46-fold difference was observed. Although the CHD subjects were unmatched, on average they were older ( years) and the burden of comorbid illness was likely higher than that of the study cohort (16,17). Therefore, the observed SAB rate in the study cohort was more likely attributable to the BHC technique itself (or its concomitant use with nocturnal HD) than to casemix differences. A comparison with patients receiving home nocturnal HD using rope-ladder cannulation would have been more informative. Because all patients in this study cohort used BHC, this was not possible. Unfortunately, such comparisons would be prone to confounding by indication. After initiation of the topical mupirocin protocol, no further systemic infections with S. aureus or any other pathogen occurred among patients
5 Clin J Am Soc Nephrol 5: , 2010 Mupirocin Prophylaxis with Buttonhole Cannulation 1051 Table 5. Patient characteristics associated with risk of SAB while using BHC with an AVF (n 56) Patient Characteristic Percent Patients with SAB (n 10) Percent Patients with no SAB (n 46) Age (years) Diabetes yes no Race white black Asian 0 15 Smoker yes 0 7 no Peripheral vascular disease yes 20 9 no Immunosuppressive therapy yes 0 7 no Hemoglobin (g/l) Albumin (g/l) Creatinine ( mol/l) Urea (mmol/l) Ferritin ( g/l) C-reactive protein (mg/l) adherent to the prescribed regimen. It is also noteworthy that no AVF failures occurred during the study period, which is in keeping with other reports of improved access longevity with BHC (18). The mechanism by which infection risk is increased in BHC is not known, but several factors may contribute. It is well established that uremia itself is associated with impaired immune function (19). Interactions between systemic and local factors may contribute to the increased infection risk associated with BHC. Local factors may include breeches in cannulation technique, skin colonization, loss of skin integrity, frequency of cannulation, and needle movement within the needle tracts (especially during sleep). Because the total number of events in our study was relatively small, it was not possible to undertake a meaningful quantitative analysis of predictors of infection. Because our program did not provide alternate-night nocturnal HD until March 2004, we could not determine the infection rate associated with alternate-night HD in the absence of mupirocin cream prophylaxis and could therefore not evaluate HD frequency as a predictor of infection risk. Among the variables reported in Table 5, only an elevated C-reactive protein at baseline appeared to be associated with infection risk. It is possible that this patient group had subclinical infections that later evolved into overt infection. The cannulation and cleansing techniques used by our program were identical to those used elsewhere (9,20,21), thus it is unlikely unique local practices contributed to the observed risk of infection. Antimicrobial cream prophylaxis has been studied in the peritoneal dialysis (PD) and CHD populations with generally favorable results. A meta-analysis of ten studies demonstrated combined risk reductions of 80% (95% CI 65% to 89%) and 63% (95% CI 50% to 73%) in HD and PD patients, respectively (22). A subsequent study found that antimicrobial cream prophylaxis in patients using CVCs for HD reduced infection rates and possibly improved patient survival (23). Despite these findings, adoption of this practice has been variable. This is likely due in part to concerns regarding the emergence of antimicrobial resistance. The incidence of mupirocin resistance among patients with regular application to PD catheter exit sites has been variable across centers and countries, with cumulative incidence rates ranging between 2.7% and 32% (24 26). Our program did not routinely screen for mupirocin resistance. However, because no infections occurred on treatment with mupirocin, it is unlikely that the prevalence high-level mupirocin resistance was significant. Low-level mupirocin resistance, although generally more common, is of limited clinical significance because the mupirocin concentration in a 2% preparation (2 g/l) safely exceeds the minimal inhibitory concentration (8 to 64 mg/l) for low-resistance organisms (27). Although mupirocin resistance can result in failure of prophylaxis, it is not independently associated with the emergence of MRSA or failure of systemic therapy for infections (28). Although it is reassuring that no MRSA infections or suspected cases of mupirocin resistance were encountered during our 11 years of observation, risk factors such as nasal carriage rates and local antimicrobial resistance patterns preclude generalization of our results to other programs. Some methodological issues merit discussion. Because of a prepost design, we cannot exclude confounding due to changes in patient adherence and cannulation technique, which may have reduced infection rates over time. This design was chosen because it allowed data for all patients followed during either or both study periods to be used. Alternatively, a cohort study design could have compared distinct patient groups followed during the two study periods. However, this would not have altered the conclusions drawn. Secondly, given the zero-event rate, the OR for the as-treated analysis (35.3, 95% CI 2.0 to
6 1052 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 5: , ) was estimated by manual computation with 0.5 added to the event rates. CIs were wide because of highly variable follow-up times. Future studies with more events and longer follow-up will provide more precise estimates of treatment efficacy. The use of alternative statistical tests, such as Fisher s exact test, would have been equally valid and would not have changed the treatment effect estimates or the conclusions drawn. Third, because of the retrospective nature of this study, missing data (missed infections or lapses in fistula use) may have resulted in an underestimate of the infection risk with BHC. Finally, confirmation of these findings with a randomized controlled clinical trial is desirable. However, given the potentially devastating consequences of infection and the relatively innocuous nature of the intervention, some practitioners may not feel there is sufficient equipoise to justify this approach. More observational data may be needed before the dialysis community will embrace a randomized trial. Comparisons between various antimicrobial preparations may be of value as well. In addition to allowing for self-cannulation, proposed benefits of BHC include decreased pain, less hematomas, improved hemostasis, increased overall patient satisfaction, resolution of aneurismal dilation (29), and improved access survival (13,18). It therefore seems likely that its use will continue to increase, particularly if home dialysis continues to proliferate. Given the relatively small number of patients currently using BHC, there would be considerable value in prospectively capturing outcome data in national registries so that more rigorous studies of infection rates and predictors of infection can be undertaken and thereby inform future clinical decision-making and research. In the meantime, rigorous surveillance by patients and their healthcare professionals is warranted. In conclusion, in this retrospective prepost study, we report a significant risk of SAB with potentially fatal metastatic complications in patients receiving home nocturnal HD with BHC. Patients considering this method should be counseled with respect to the potential risks. While awaiting more rigorous studies of efficacy and safety, topical mupirocin prophylaxis should be considered for patients using this cannulation technique. Acknowledgments The authors wish to thank the three anonymous reviewers for their insightful suggestions. We also respectfully acknowledge the pioneering work of Dr. Zbylut Twardowski in establishing the buttonhole cannulation technique. This study was presented in abstract form at the annual meeting of the American Society of Nephrology; San Diego, CA; October 27 through November 1, Disclosures None. References 1. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, Rayner HC, Saito A, Sands JJ, Saran R, Gillespie B, Wolfe RA, Port FK: Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: An instrumental variable analysis. Am J Kidney Dis 53: , Mendelssohn DC, Yeates KE, Ethier J, Trpeski L, Na Y, Bragg-Gresham JL, Eichleay MA, Pisoni RL, Port FK: DOPPS estimate of patient life years attributable to modifiable hemodialysis practices in Canada. Nephrol News Issues 21: 69 70, 72, passim, Dhingra RK, Young EW, Hulbert-Shearon TE, Leavey SF, Port FK: Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 60: , Perera GB, Mueller MP, Kubaska SM, Wilson SE, Lawrence PF, Fujitani RM: Superiority of autogenous arteriovenous hemodialysis access: Maintenance of function with fewer secondary interventions. Ann Vasc Surg 18: 66 73, Polkinghorne KR, McDonald SP, Atkins RC, Kerr PG: Vascular access and all-cause mortality: A propensity score analysis. J Am Soc Nephrol 15: , Woods JD, Port FK: The impact of vascular access for haemodialysis on patient morbidity and mortality. Nephrol Dial Transplant 12: , Twardowski Z: Different sites versus constant sites of needle insertion into arteriovenous fistulas for treatment of repeated dialysis. Dial Transplant 8: , Twardowski Z: Constant site (buttonhole) method of needle insertion for hemodialysis. Dial Transplant 24: : 576, Ball LK: The buttonhole technique for arteriovenous fistula cannulation. Nephrol Nurs J 33: , Twardowski ZJ: Utility of the buttonhole cannulation method for hemodialysis patients with arteriovenous fistulas. Nat Clin Pract Nephrol 3: , Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, Langos V, Uldall R: Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol 9: , Pierratos A: Nocturnal home haemodialysis: An update on a 5-year experience. Nephrol Dial Transplant 14: , Verhallen AM, Kooistra MP, van Jaarsveld BC: Cannulating in haemodialysis: rope-ladder or buttonhole technique? Nephrol Dial Transplant 22: , Lindsay RM, Leitch R, Heidenheim AP, Kortas C: The London Daily/Nocturnal Hemodialysis Study Study design, morbidity, and mortality results. Am J Kidney Dis 42: 5 12, Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S: Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control 32: , Nesrallah GE, Suri RS, Carter ST, Moist LM, Garg AX, Awaraji C, Lindsay RM: The International Quotidian Dialysis Registry: Annual report Hemodial Int 11: , Nesrallah GE, Suri RS, Zoller R, Garg AX, Moist LM, Lindsay RM: The International Quotidian Dialysis Registry: Annual report Hemodial Int 10: , van Loon MM, Goovaerts T, Kessels AG, van der Sande FM, Tordoir JH: Buttonhole needling of haemodialysis arteriovenous fistulae results in less complications and interventions compared to the rope-ladder technique. Nephrol Dial Transplant 25: , 2010
7 Clin J Am Soc Nephrol 5: , 2010 Mupirocin Prophylaxis with Buttonhole Cannulation Hauser AB, Stinghen AE, Kato S, Bucharles S, Aita C, Yuzawa Y, Pecoits-Filho R: Characteristics and causes of immune dysfunction related to uremia and dialysis. Perit Dial Int 28[Suppl 3]: S183 S187, Ball LK, Treat L, Riffle V, Scherting D, Swift L: A multicenter perspective of the buttonhole technique in the Pacific northwest. Nephrol Nurs J 34: , Leitch R, Ouwendyk M, Ferguson E, Clement L, Peters K, Heidenheim AP, Lindsay RM: Nursing issues related to patient selection, vascular access, and education in quotidian hemodialysis. Am J Kidney Dis 42: 56 60, Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D Agata EM: Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: A meta-analysis. Clin Infect Dis 37: , Lok CE, Stanley KE, Hux JE, Richardson R, Tobe SW, Conly J: Hemodialysis infection prevention with polysporin ointment. J Am Soc Nephrol 14: , Conly JM, Vas S: Increasing mupirocin resistance of Staphylococcus aureus in CAPD Should it continue to be used as prophylaxis? Perit Dial Int 22: , Lobbedez T, Gardam M, Dedier H, Burdzy D, Chu M, Izatt S, Bargman JM, Jassal SV, Vas S, Brunton J, Oreopoulos DG: Routine use of mupirocin at the peritonealcatheter exit site and mupirocin resistance: Still low after 7 years. Nephrol Dial Transplant 19: , Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdes F: Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39: , Patel JB, Gorwitz RJ, Jernigan JA: Mupirocin resistance. Clin Infect Dis 49: , Harbarth S, Liassine N, Dharan S, Herrault P, Auckenthaler R, Pittet D: Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 31: , Marticorena RM, Hunter J, Macleod S, Petershofer E, Dacouris N, Donnelly S, Goldstein MB: The salvage of aneurysmal fistulae utilizing a modified buttonhole cannulation technique and multiple cannulators. Hemodial Int 10: , 2006
7/7/2015. Objectives. Pros and Cons of Buttonhole Cannulation
Objectives Pros and Cons of Buttonhole Cannulation Charmaine Lok, MD, FRCPC, MSc University of Toronto Toronto General Hospital To gain an appreciation of the importance of proper vascular access cannulation
More informationSichol sooksee,rn. Hemodialysis Unit Rajavej Chiang Mai Hospital
Sichol sooksee,rn. Hemodialysis Unit Rajavej Chiang Mai Hospital Button hole or Ladder?? Vascular Access Cannulation It s a Life Line of Hemodialysis patient Arterio-venous fistula(avf) is the K/DOQI
More informationPreservation of Veins and Timing for Vascular Access
Preservation of Veins and Timing for Vascular Access Vassilis Liakopoulos, MD, PhD Department of Nephrology School of Medicine University of Thessaly Greece Hemodialysis VA A sound long-term dialysis access
More informationButtonhole needling of haemodialysis arteriovenous fistulae results in less complications and interventions compared to the rope-ladder technique
Nephrol Dial Transplant (2010) 25: 225 230 doi: 10.1093/ndt/gfp420 Advance Access publication 29 August 2009 Buttonhole needling of haemodialysis arteriovenous fistulae results in less complications and
More informationDoes cannulation technique impact arteriovenous fistula and graft survival? Maria Teresa Parisotto CANNT 2017 Halifax October 20 th, 2017
Does cannulation technique impact arteriovenous fistula and graft survival? Maria Teresa Parisotto CANNT 2017 Halifax October 20 th, 2017 Survival Preserving the AVF as the patient lifeline: reduced mortality
More informationButtonhole: The Evidence and How to Implement. Lynda K. Ball, MSN, RN, CNN October 1, 2014 Aarhus, Denmark
Buttonhole: The Evidence and How to Implement Lynda K. Ball, MSN, RN, CNN October 1, 2014 Aarhus, Denmark Sticking an Access More Frequently Several older studies reveal access longevity compares favorably
More informationEffect of Buttonhole Cannulation With a Polycarbonate Peg on In-Center Hemodialysis Fistula Outcomes: A Randomized Controlled Trial
Original Investigation Effect of Buttonhole Cannulation With a Polycarbonate Peg on In-Center Hemodialysis Fistula Outcomes: A Randomized Controlled Trial Emma Vaux, MD, PhD, 1 Jennie King, RN, BSc(Hons),
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM
ASN DIALYSIS ADVISORY GROUP ASN DIALYSIS CURRICULUM Medical Management of Home Hemodialysis Patients Brent W. Miller, MD Professor of Medicine Washington University School of Medicine Saint Louis, Missouri
More informationArteriovenous fistula cannulation by buttonhole technique using dull needle
Original Article Arteriovenous fistula cannulation by buttonhole technique using dull needle Authors Manuel Carlos Martins de Castro 1 Celina de Fátima e Silva 1 João Marcos Rodrigues de Souza 1 Maria
More informationTechnical and Clinical Barriers to Implementing an Optimal Case Mix of Vascular Access
Technical and Clinical Barriers to Implementing an Optimal Case Mix of Vascular Access Louise Moist Associate Professor Lead Vascular Access Ontario Renal Network Schulich School of Medicine University
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationHospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia
Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia Amanda Guth 1 Amy Slenker MD 1,2 1 Department of Infectious Diseases, Lehigh Valley Health Network
More informationVascular Access Profile in Maintenance Hemodialysis Patients
DIALYSIS Vascular Access Profile in Maintenance Hemodialysis Anoop Gowda, 1 Malleshappa Pavan, 2 Kishore Babu 3 Original Paper 1 Division of Nephrology, Department of Medicine, Dr BR Ambedkar Medical College
More informationJVA ISSN Hemodialysis vascular access management in the Netherlands. Introduction ORIGINAL ARTICLE
JVA ISSN 1129-7298 J Vasc Access 2015; 16 (Suppl 9): S11-S15 DOI: 10.5301/jva.5000366 ORIGINAL ARTICLE Hemodialysis vascular access management in the Netherlands Jan H.M. Tordoir 1, Magda M. van Loon 1,
More informationBAPN 2016 Audit of dialysis access and complications in UK children
BAPN 2016 Audit of dialysis access and complications in UK children Version 2, 8 th Dec 2015 Yincent Tse, BAPN audit committee member, yincenttse@nhs.net Introduction For children on dialysis, their access
More informationEmerging Technology List PORTABLE HOME HEMODIALYSIS
NO. 25 MARCH 2005 Technology: Manufacturer: Purpose: Current Regulatory Status: Description: Portable home hemodialysis devices Home Dialysis Plus (HD+), Home Dialysis Plus, Ltd., Portland OR; PHD Personal
More informationState Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE
Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for
More informationDialysis Adequacy (HD) Guidelines
Dialysis Adequacy (HD) Guidelines Peter Kerr, Convenor (Monash, Victoria) Vlado Perkovic (Camperdown, New South Wales) Jim Petrie (Woolloongabba, Queensland) John Agar (Geelong, Victoria) Alex Disney (Woodville,
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationHaemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014
Haemophilus influenzae Surveillance Report 2012 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: July 2014 Background The Active Bacterial Core surveillance (ABCs)
More informationFistula/Graft Protection. Leslie Dork Renal Medicine Associates
+ Fistula/Graft Protection Leslie Dork Renal Medicine Associates + Disclaimer Renal Medicine Associates employee I have no conflicts of interest. + Access failure Infections Infiltrations Stenoses/Thrombosis
More informationAMMAR SERAWAN, MD. Ain Wzain Hospital. April 21, 2012 Vascular Access Study Workshop
AMMAR SERAWAN, MD Ain Wzain Hospital April 21, 2012 Vascular Access Study Workshop 1 Inspection for signs of: - infection (redness, discharge, edema) -aneurysms (may be cannulated using the lateral side
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationSUCCESSFUL VASCULAR ACCESS MANAGEMENT FOR HOME HAEMODIALYSIS: A PRACTICAL APPROACH
CLINICAL PRACTICE SUCCESSFUL VASCULAR ACCESS MANAGEMENT FOR HOME HAEMODIALYSIS: A PRACTICAL APPROACH Annemarie Verhallen Dianet Dialysis Centers, Utrecht, The Netherlands Verhallen A. (2013). Successful
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationEvidence Table. Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis.
Evidence Table Clinical Area: Reference: Frequent home dialysis Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass
More informationMANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION
MANAGEMENT OF HAEMODIALYSIS CATHETER RELATED BLOOD STREAM INFECTION RRCV CMG Renal and Transplant Service 1. Introduction Catheter related blood stream infection (CR-BSI) is a common complication in patients
More informationCHAPTER 5. Haemodialysis. Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald
CHAPTER Haemodialysis Kevan Polkinghorne Hannah Dent Aarti Gulyani Kylie Hurst Stephen McDonald STOCK AND FLOW AUSTRALIA The annual stock and flow of HD patients during the period - is shown in Figures.,.
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Serum phosphate GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Serum phosphate GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationMeeting the Guidelines for End-of-Life Care
Advances in Peritoneal Dialysis, Vol. 22, 2006 Gillian Brunier, David M.J. Naimark, Michelle A. Hladunewich Meeting the Guidelines for End-of-Life Care The number of patients initiating dialysis in most
More informationLesson #7: Quality Assessment and Performance Improvement
ESRD Update: Transitioning to New ESRD Conditions for Coverage Student Manual Lesson #7: Quality Assessment and Performance Improvement Learning Objectives At the conclusion of this lesson, you will be
More informationThe Renal Physicians Association Quality Improvement Registry
In collaboration with CECity The Renal Physicians Association Quality Improvement Registry This registry is approved by CMS as a Qualified Clinical Data Registry (QCDR) for Eligible Professionals and GPRO
More informationChapter 7 The Relationship between the type of Vascular Access used and Survival in UK RRT Patients in 2006
Chapter 7 The Relationship between the type of Vascular Access used and Survival in UK RRT Patients in 2006 Clare Castledine, Dirk van Schalkwyk, Terry Feest UK Renal Registry, Bristol, UK Key Words Arterio-venous
More informationDavid C. Mendelssohn MD, FRCPC DOPPS Update 2010
David C. Mendelssohn MD, FRCPC DOPPS Update 2010 Budapest Nephrology School August 30, 2010 Overview 1) General aspects of DOPPS 2) Facility based analysis 3) High hemoglobin 4) Coumadin use 5) Summary
More informationThe Buttonhole Technique for AV Fistula Cannulation
The Buttonhole Technique for AV Fistula Cannulation Lynda K. Ball, RN, MSN, CNN October 16 & 17, 2008 Trends in Nephrology Nursing Kaiser Permanente Acute Dialysis Symposium 1 CMS Disclaimer This publication
More informationCHAPTER 6 PERITONEAL DIALYSIS. Neil Boudville. Hannah Dent. Stephen McDonald. Kylie Hurst. Philip Clayton Annual Report - 36th Edition
CHAPTER 6 Neil Boudville Hannah Dent Stephen McDonald Kylie Hurst Philip Clayton 213 Annual Report - 36th Edition ANZDATA Registry 213 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis was used to treat
More informationInfected cardiac-implantable electronic devices: diagnosis, and treatment
Infected cardiac-implantable electronic devices: diagnosis, and treatment The incidence of infection following implantation of cardiac implantable electronic devices (CIEDs) is increasing at a faster rate
More informationModifiable Risk Factors in Orthopaedic Infections
Modifiable Risk Factors in Orthopaedic Infections AAOS Patient Safety Committee Burden US Surgical Site Infections (SSI) by the Numbers ~300,000 SSIs/yr (17% of all HAI; second to UTI) 2%-5% of patients
More informationReviews in Infection
Reviews in Infection RIF 1(1):1-6 (2010) RIF ISSN:1837-6746 Original Research Infection related processes during haemodialysis: A study in General Hospital Haemodialysis unit Naser Hussain 1, *Mona F.
More informationNorth American Pediatric Renal Trials Collaborative Studies Production Release Registration (DEM) Web Version: 1.0; 1.
Registration (DEM) Web Version: 1.0; 1.4; 06-20-13 1. Does your site participate in the NAPRT CS Registries? 1- No 2- Yes 2. Date of birth: (mm/dd/yyyy) 3. Race/ethnicity: 4. Gender: 1-Male 2-Female 5.
More informationMANITOBA RENAL PROGRAM
SUBJECT Venipuncture of Arteriovenous Fistula/Graft MANITOBA RENAL PROGRAM SECTION CODE 30.20.01 30.20 Vascular Access AUTHORIZATION Professional Advisory Committee, Manitoba Renal Program Nursing Practice
More informationAssisted Peritoneal Dialysis
Assisted Peritoneal Dialysis BC Kidney Days Vancouver, BC Matthew Oliver MD MHS Sunnybrook Health Sciences Centre University of Toronto Oct 18, 2012 Declaration 2 Co-inventor of the Dialysis Measurement
More informationNephrology. ABC Fax Marie Philipneri Ziyad Al Aly Kamal Amin Mary E. Gellens Bahar Bastani
American Journal of Nephrology Original Article: Patient-Oriented, Translational Research Am J Nephrol 2003;23:202 207 DOI: 10.1159/000071479 Received: April 1, 2003 Accepted: April 9, 2003 Published online:
More information3/5/18. Background. Registry Reports. Dialysis Registry Update and Future Directions
Dialysis Registry Update and Future Directions Annabelle N. Chua, MD March 4, 2018 Background Founded in 1987 as a transplant registry Expanded registry to include dialysis (1992) and CKD (1994) Patient
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationEnhancement of Infection Control for MRSA in Renal Unit
Enhancement of Infection Control for MRSA in Renal Unit Ms Ida Yip SNO (Infection Control) Hong Kong East Cluster Hospital 19 August 2011 IC Forum (19-8-2011) 1 MRSA Common Multi Drug Resistant Organisms
More informationCannulating AV Fistula using Buttonhole Technique
Nephrology Directorate Subject: Objective: Prepared by: Cannulating AV Fistula using Buttonhole Technique To enable the safe insertion and removal of needles into arteriovenous fistulae using the buttonhole
More informationChapter six Outcomes: hospitalization & mortality. There is an element of death in life, and I am astonished
INTRODUCTION 1 OVERALL HOSPITALIZATION & MORTALITY 1 hospital admissions & days, by primary diagnosis & patient vintage five-year survival mortality rates, by patient vintage expected remaining lifetimes
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2001 [Before completing please read instructions at the bottom of this page and on pages 4 and 5] PATIENT IDENTIFICATION MAKE
More informationFocus su: Accessi Vascolari. dr Carlo Lomonte U.O.C. di Nefrologia e Dialisi Ente Ecclesiastico Ospedale Miulli Acquaviva delle Fonti - Ba
Focus su: Accessi Vascolari dr Carlo Lomonte U.O.C. di Nefrologia e Dialisi Ente Ecclesiastico Ospedale Miulli Acquaviva delle Fonti - Ba Sommario Epidemiologia dell Accesso Vascolare L Accesso Vascolare
More information03/20/2019. Thank you for the invitation to speak. I have no conflicts of interest
Raj Munshi, MD Annual Dialysis Conference 2019 Thank you for the invitation to speak I have no conflicts of interest Expected remaining lifetime in years of prevalent patients by initial ESRD modality,
More informationHome Dialysis. Peritoneal Dialysis. Home Hemodialysis
Home Dialysis The information provided is not intended to be a substitute for professional medical advice. A licensed healthcare professional should be consulted for diagnosis and treatment of any and
More informationCLINICAL GUIDELINES SUPPORTING THE USE OF BUTTONHOLE NEEDLING at SaTH NHS Trust
CLINICAL GUIDELINES SUPPORTING THE USE OF BUTTONHOLE NEEDLING at SaTH NHS Trust Lead Clinician: Dr Steve Davies Renal Consultant Division: 1 (Unscheduled Care) Implementation date: 16 th September 2014
More informationClinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01622.x Clinical outcome and costs of nosocomial and community-acquired Staphylococcus aureus bloodstream infection in haemodialysis patients W. Greiner 1, A.
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationApril 18, Dear Mr. Blum and Dr. Conway:
April 18, 2014 Dear Mr. Blum and Dr. Conway: On behalf of the undersigned patient and health professional organizations, thank you for meeting with us Wednesday, September 18, 2013. Our organizations were
More information02/10/2017. Major Infectious Complications. Learning Objectives. Modalities. At the end of this session the listener will be able to:
Major Infectious Complications Alicia M Neu, MD Chief, Division of Pediatric Nephrology Medical Director, Pediatric Dialysis and Kidney Transplantation The Johns Hopkins University School of Medicine The
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Mode of dialysis at initiation GUIDELINES
Date written: September 2004 Final submission: February 2005 Mode of dialysis at initiation GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationDialysis Event Protocol
Dialysis Event Protocol Introduction In 2009, more than 370,000 patients were treated with maintenance hemodialysis in the United States. 1 Hemodialysis patients require a vascular access, which can be
More informationManagement of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy.
Management of Catheter Related Bloodstream Infection (CRBSI), including Antibiotic Lock Therapy. Written by: Dr K Gajee, Consultant Microbiologist Date: June 2017 Approved by: Drugs & Therapeutics Committee
More informationOf 142 cases where sex was known, 56 percent were male; of 127cases where race was known, 90 percent were white, 4 percent were
Group B Streptococcus Surveillance Report 2014 Oregon Active Bacterial Core Surveillance (ABCs) Center for Public Health Practice Updated: November 2015 Background The Active Bacterial Core surveillance
More informationASDIN 7th Annual Scientific Meeting
Strategies for Decreasing the Use of Hemodialysis Catheters ASDIN 7 th Annual Scientific Meeting Outline Late referral Primary failure Why Not PD? Summary Micah Chan MD MPH FACP Assistant Professor of
More informationGender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices
Original Articles Gender, low Kt/V, and mortality in Japanese hemodialysis patients: Opportunities for improvement through modifiable practices Naoki KIMATA, 1 Angelo KARABOYAS, 2 Brian A. BIEBER, 2 Ronald
More informationIncreased Hemodialysis Catheter Use in Canada and Associated Mortality Risk: Data from the Canadian Organ Replacement Registry
Increased Hemodialysis Catheter Use in Canada and Associated Mortality Risk: Data from the Canadian Organ Replacement Registry 2001 2004 Louise M. Moist,* Lilyanna Trpeski, Yingbo Na, and Charmaine E.
More informationChapter 2 Peritoneal Equilibration Testing and Application
Chapter 2 Peritoneal Equilibration Testing and Application Francisco J. Cano Case Presentation FW, a recently diagnosed patient with CKD Stage 5, is a 6-year-old boy who has been recommended to initiate
More informationBUTTONHOLE CANNULATION
BUTTONHOLE CANNULATION What is a Buttonhole? Technique in which an AV fistula is cannulated in the exact same spot, at the same angle and at the same depth of penetration every time. Benefits Reduction
More informationMANITOBA RENAL PROGRAM
SUBJECT Venipuncture of Arteriovenous Fistula/Graft MANITOBA RENAL PROGRAM SECTION CODE 30.30.01 30.30 Vascular Access AUTHORIZATION Professional Advisory Committee, Manitoba Renal Program Nursing Practice
More informationNursing Care of the Dialysis Patient. Adrian Hordon, MSN, RN
Nursing Care of the Dialysis Patient Adrian Hordon, MSN, RN Understand principles of hemodialysis Recognize different access ports Identify side effects and complications Discuss nursing care for pre and
More informationAdvances in Peritoneal Dialysis, Vol. 23, 2007
Advances in Peritoneal Dialysis, Vol. 23, 2007 Antonios H. Tzamaloukas, 1,2 Aideloje Onime, 1,2 Dominic S.C. Raj, 2 Glen H. Murata, 1 Dorothy J. VanderJagt, 3 Karen S. Servilla 1,2 Computation of the Dose
More informationUrgent start PD: Putting the person first
Urgent start PD: Putting the person first Arsh Jain MD, FRCPC, MSc ADC 2019 Who can we target with urgent start PD? Late or not referred Early referral Urgent dialysis start HD catheter Facility HD Who
More informationAlternative hemodialysis regimens
REVIEW ARTICLE Alternative hemodialysis regimens Authors Jorge Paulo Strogoff de Matos 1 Jocemir Ronaldo Lugon 2 1 Center of Dialysis and Transplantation, Division of Nephrology, Hospital Universitário
More informationSafety of Targeted Perioperative Mupirocin Treatment for Preventing Infections After Cardiac Surgery
Safety of Targeted Perioperative Mupirocin Treatment for Preventing Infections After Cardiac Surgery Nabin K. Shrestha, MD, Michael K. Banbury, MD, Monica Weber, MSN, Roberta E. Cwynar, BSN, Cheryl Lober,
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Blood urea sampling methods GUIDELINES
Date written: November 2004 Final submission: July 2005 Blood urea sampling methods GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions are
More informationCanadian Society of Nephrology Guidelines for the Management of Patients With ESRD Treated With Intensive Hemodialysis
CSN Guideline Canadian Society of Nephrology Guidelines for the Management of Patients With ESRD Treated With Intensive Hemodialysis Gihad E. Nesrallah, MD, 1 * Reem A. Mustafa, MD, MPH, 2 * Jennifer MacRae,
More informationExperts in all modalities The Expanding Role of PD Trends and Advances That Have Increased the Viability and Utilization of Peritoneal Dialysis
Experts in all modalities The Expanding Role of PD Trends and Advances That Have Increased the Viability and Utilization of Peritoneal Dialysis Todd W.B. Gehr, M.D. Professor and Chairman, Division of
More informationTITLE: Antimicrobial Ointments for Patients Undergoing Hemodialysis: A Review of Evidence-Based Guidelines
TITLE: Antimicrobial Ointments for Patients Undergoing Hemodialysis: A Review of Evidence-Based Guidelines DATE: 20 June 2013 CONTEXT AND POLICY ISSUES Vascular access is an important concern in patients
More informationCHAPTER 6 PERITONEAL DIALYSIS. Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst Annual Report 35th Edition
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst 212 Annual Report 35th Edition PERITONEAL DIALYSIS ANZDATA Registry 212 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis
More informationCannulation Techniques Webinar
Cannulation Techniques Webinar March 28, 2012 ESRD Network of Texas Lynda K. Ball, MSN, RN, CNN Objectives Discuss assessment skills inspection, palpation, and auscultation of an AV fistula to determine
More informationIncidence per 100,
Group B Streptococcus Surveillance Report 2005 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services Updated: January 2007 Background
More informationHaemodialysis central venous catheter-related sepsis management guideline Version 3. NAME M. Letheren Chair Clinical Effectiveness Advisory Group
Lancashire Teaching Hospitals NHS Foundation Trust Haemodialysis central venous catheter-related sepsis management guideline Version 3 AUTHOR APPROVED BY DATE AUTH REF. NO NAME REBG/00018/July12 Michael
More informationQuality of sleep in patients with chronic kidney disease
Nephrol Dial Transplant (2004) 19: 95 99 DOI: 10.1093/ndt/gfg423 Original Article Quality of sleep in patients with chronic kidney disease Eduard A. Iliescu, Karen E. Yeates and David C. Holland Department
More informationSafety of arteriovenous fistulae and grafts for continuous renal replacement therapy: The Michigan experience
Hemodialysis International 2018; 22:50 55 Original Article Access Safety of arteriovenous fistulae and grafts for continuous renal replacement therapy: The Michigan experience Anas AL RIFAI, 1,2 Nidhi
More informationFinal published version:
Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: A retrospective cohort study Laura Plantinga, Emory University
More informationVariable Included. Excluded. Included. Excluded
Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients
More informationNational Surveillance System for Dialysis Centre and Dialysis Associated Diseases
National Surveillance System for Dialysis Centre and Dialysis Associated Diseases Dr Richard Fluck Consultant Renal Physician & Clinical Director, Royal Derby Hospital UK RA Vascular Access Survey 2005
More informationFrequency of Nasal Carriage of Staphylococcus Aureus and Its Antimicrobial Resistance Pattern in Patients on Hemodialysis
Dialysis Frequency of Nasal Carriage of Staphylococcus Aureus and Its Antimicrobial Resistance Pattern in Patients on Hemodialysis Roya Ghasemian, 1 Narges Najafi, 1 Atieh Makhlough, 2 Mohammad Khademloo
More informationTHE CURRENT PARADIGM of thrice-weekly
Dose of Dialysis: Key Lessons From Major Observational Studies and Clinical Trials Rajiv Saran, MD, MS, Bernard J. Canaud, MD, Thomas A. Depner, MD, Marcia L. Keen, PhD, Keith P. McCullough, MS, Mark R.
More informationMANITOBA RENAL PROGRAM
MANITOBA RENAL PROGRAM SUBJECT Use of Closed Needleless Access Device with Hemodialysis Central Venous Catheters (CVC) SECTION CODE 30.20.04 30.20 Vascular Access AUTHORIZATION Professional Advisory Committee,
More informationButtonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review
Article Buttonhole Cannulation and Clinical Outcomes in a Home Hemodialysis Cohort and Systematic Review Christopher A. Muir,* Sradha S. Kotwal,* Carmel M. Hawley, Kevan Polkinghorne, Martin P. Gallagher,*
More informationWhat s on the Horizon in Dialysis Access? Libby Watch, MD, FACS Miami Cardiac & Vascular Institute
What s on the Horizon in Dialysis Access? Libby Watch, MD, FACS Miami Cardiac & Vascular Institute Disclosures No relevant disclosures Employee Advanced Access Care Dialysis Work 5 operating surgeons 3
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationHeart on Fire: Infective Endocarditis. Objectives. Disclosure 8/27/2018. Mary McGreal DNP, RN, ANP-c, CCRN
Heart on Fire: Infective Endocarditis Mary McGreal DNP, RN, ANP-c, CCRN Objectives Discuss the incidence of infective endocarditis? Discuss the pathogenesis of infective endocarditis? Discuss clinical
More informationAssociation of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis
Article Association of Vascular Access Type with Mortality, Hospitalization, and Transfer to In-Center Hemodialysis in Patients Undergoing Home Hemodialysis Matthew B. Rivara,* Melissa Soohoo, Elani Streja,
More information2015 Children's Mercy Hospitals and Clinics. All Rights Reserved.
Growth van Stralen KJ, et al., Kidney Int, 2014 Blood Pressure Management van Stralen KJ, et al., Kidney Int, 2014 Sodium Losses on PD Infants might need higher UF rate per BSA as compared to adults to
More informationEffects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes
Original Investigation Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Eduardo Lacson Jr, MD, MPH, Weiling Wang, MS, Cari DeVries, Keith
More informationEnd-Stage Renal Disease. Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology
End-Stage Renal Disease Anna Vinnikova, M.D. Associate Professor of Medicine Division of Nephrology ESRD : Life with renal replacement therapy CASE: 18 month old male with HUS develops ESRD PD complicated
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationWorld Congress of Nephrology, Mexico City
World Congress of Nephrology, Mexico City - 2017 Introduction To study the prevalence and incidence of Hepatitis B and C in a dialysis cohort and analyse factors that cause cross-infection. Methods A total
More informationPREDICTORS OF PERITONITIS AMONG CANADIAN PERITONEAL DIALYSIS PATIENTS
PREDICTORS OF PERITONITIS AMONG CANADIAN PERITONEAL DIALYSIS PATIENTS By Sharon J. Nessim, MD A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department
More information